Emerging viruses and current strategies for vaccine intervention. by Afrough, B et al.
157© 2019 Crown copyright. Clinical and Experimental Immunology © 2019 British Society for Immunology.
This article is published with the permission of the Controller of HMSO and the Queen’s Printer for Scotland, 
Clinical and Experimental Immunology, 196: 157–166
Emerging viruses and current strategies for vaccine intervention
B. Afrough, S. Dowall and  
R. Hewson
Virology and Pathogenesis Laboratory, 
National Infection Service, Public Health 
England, Salisbury, UK. 
Accepted for publication 14 March 2019 
Correspondence: R. Hewson, Virology and 
Pathogenesis Laboratory, National Infection 
Service, Public Health England, Porton 
Down, Salisbury, Wiltshire SP4 0JG, UK. 
E-mail: roger.hewson@phe.gov.uk 
Summary
During the past decade several notable viruses have suddenly emerged 
from obscurity or anonymity to become serious global health threats, 
provoking concern regarding their sustained epidemic transmission in 
immunologically naive human populations. With each new threat comes 
the call for rapid vaccine development. Indeed, vaccines are considered a 
critical component of disease prevention for emerging viral infections 
because, in many cases, other medical options are limited or non-existent, 
or that infections result in such a rapid clinical deterioration that the 
effectiveness of therapeutics is limited. While classic approaches to vaccine 
development are still amenable to emerging viruses, the application of 
molecular techniques in virology has profoundly influenced our under-
standing of virus biology, and vaccination methods based on replicating, 
attenuated and non-replicating virus vector approaches have become useful 
vaccine platforms. Together with a growing understanding of viral disease 
emergence, a range of vaccine strategies and international commitment 
to underpin development, vaccine intervention for new and emerging 
 viruses may become a possibility.
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Introduction
Immunization is arguably the most appropriate way of 
preventing infectious disease. The control of many impor-
tant viral pathogens by vaccination is perhaps one of the 
outstanding achievements of medical intervention.
Vaccine-induced immunity that is established in advance 
of virus infection relies primarily on adaptive immune 
responses for protective efficacy. Critically, vaccination 
depends on the properties of antigen recognition, activa-
tion, expansion, memory, trafficking and the multitude of 
specialist functions of lymphocytes. The extent to which 
vaccine-induced immunity is successful also determines 
the spread and maintenance of a viral pathogen within a 
population. Viral vaccines have had profound and endur-
ing consequences for human and animal health; the world-
wide eradication of smallpox and rinderpest are testament 
to their outstanding contribution to modern society.
Nevertheless, infectious diseases still pose one of the 
greatest threats to public health, and the past three 
decades have brought a constant barrage of new human 
pathogens. More than 70% of these infections are zoonotic 
[1,2], entering either directly from wildlife reservoirs or 
indirectly via an intermediate domestic animal host [1,3]. 
HIV, avian influenza, Hendra (HeV) and Nipah (NiV) 
viruses, severe acute respiratory syndrome (SARS) and 
Middle East respiratory syndrome coronavirus (MERS-
CoV), Ebola and Marburg filoviruses, Lassa virus (LASV), 
Rift Valley fever virus (RVFV) and Crimean–Congo haem-
orrhagic fever (CCHF) viruses are all examples of zoonoses 
currently emerging from wildlife. All these emerging 
zoonoses present a serious and increasing threat to health, 
biosecurity and economies worldwide. The mechanisms 
underlying disease transmission from animals to humans 
are becoming better understood [4] with the emergence 
of pathogens from wildlife (which represents the greatest 
threat to global health) occurring in a non-uniform pat-
tern, being localized to distinct geographic ‘hotspots’ in 
Africa, Asia and South America, and with each high-threat 
pathogen being weighted towards a key wildlife species 
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(e.g. bats, rodents or non-human primates (NHPs). It is 
clear that such diseases will continue to place a substantial 
burden on global health, especially in dense human popu-
lations where the pressures on environmental and economic 
resources are greatest. More than one billion cases of 
human zoonotic disease are estimated to occur annually, 
and emerging zoonoses result in enormous economic losses 
[5]. Increased urbanization, international travel, commerce 
and climate change increase the likelihood that emerging 
zoonosis will continue, if not worsen, in the future.
When a zoonotic virus spills over into a susceptible 
new species, it often has the advantage that the new 
host has little or no pre-existing immunity, enabling 
attachment, entry and replication of the virus in recep-
tive cells. The amplified virus may then evade clearance 
by host defences for long enough to be transmitted to 
another susceptible host, and the lack of herd immunity 
will result in a rapid dissemination of the virus, leading 
to disease in more virulent cases of infection. Each step 
in the process represents an opportunity for vaccine-
induced immunity and, through such intervention, trans-
mitters and susceptible hosts are removed from a 
population by the pre-emptive development of protective 
immunity, so that the spread of infection becomes less 
likely. Vaccination is therefore a powerful strategy for 
preventing and controlling emerging zoonotic infectious 
disease. The development of vaccines for such emerging 
infections, however, needs to contend with several key 
challenges associated with such viruses. An emerging 
infection may be a recently discovered virus and the 
result of a rare outbreak for which basic biological infor-
mation such as correlates of protection, antigenic vari-
ability or immunodominance are unknown. There may 
be a lack of time to develop an appropriate animal model 
of disease in which to study viral immunology and evalu-
ate vaccine candidates for preclinical assessment of pro-
tective efficacy and safety. Additionally, many emerging 
viruses have high case fatality rates, spread easily and 
cannot be treated. These characteristics mandate that all 
experimental investigations with such infectious material 
be carried out at high levels of bio-safety, such as BioSafety 
levels 3 or 4. For such pathogens the availability of 
resource-heavy laboratory infrastructure is a bottleneck 
to basic research. Moreover, the often standard vaccine 
approach of using attenuated strains or inactivated viral 
vaccines is not always a feasible option, because of the 
possibility of reversion to virulence or the requirement 
for large-scale culture and production in high contain-
ment facilities. In addition to these significant hurdles, 
the economic cost of novel human vaccine development 
for rare pathogens, which are unlikely to provide an 
effective payback on investment, has been a major impedi-
ment to progress. Thus, basic research into many emerging 
pathogens has been neglected for years.
In 2014 the unpredicted size, speed and reach of the 
Ebola virus outbreak in West Africa [6] acted as a wake-
up call for researchers, pharmaceutical communities and 
governments, emphasizing the importance of investment 
into the study of emerging pathogens. Spurred on by this 
development and at the request of its 194 Member States 
in May 2015, the World Health Organization (WHO) 
convened a broad coalition of experts to develop a research 
and development (R&D) Blueprint for Action to Prevent 
Epidemics. Focusing on severe emerging diseases with the 
potential to generate public health emergencies, and for 
which no, or insufficient, preventive and curative solutions 
exist, the R&D Blueprint specifies R&D needs, including 
vaccine research. Through international governance, the 
programme aims to define R&D roadmaps for prioritized 
pathogens and to catalyse funding strategies [7].
Current vaccine platform strategies
Key to the development of successful and effective vac-
cines is the design of an antigen delivery system that 
optimizes antigen presentation and induces broad protec-
tive immune responses. Recent advances in vector delivery 
technologies, immunology and basic virology have led to 
a deeper understanding of the molecular and cellular 
mechanisms by which vaccines should stimulate both arms 
of the adaptive immune response, thereby offering novel 
strategies of vaccination. Here we discuss some current 
vaccine approaches for safe and effective vaccines encom-
passing recombinant virus technology, nucleic acid vaccines 
and self-disseminating vaccine approaches.
Viral vector technology
Advances in recombinant virology and virus reverse genet-
ics have provided key insights into the replication and 
pathogenesis of a wide range of viruses. Notably, these 
have facilitated the development of vectors for protein 
expression and vaccination. To date, several virus families 
have been exploited as vectors [8–11] including many 
for vaccination [12–15] Fig 1. A basic advantage of viral 
vectored vaccines is that the choice antigen is expressed 
in the context of an active heterologous viral infection, 
which stimulates the full gamut of innate immune responses 
required for the development of adaptive humoral and 
T cell-mediated immunity [9].
An important aspect of a virus-vectored vaccine for 
emerging viruses is that the characteristics, type and 
intensity of the immune response, as well as safety con-
siderations and manufacturing techniques are determined 
predominantly by the vector and not the pathogen. 
Therefore, developing and testing a vaccine against a newly 
discovered virus can be significantly shortened by the use 
of a viral vector platform with an extensive record of 
safety and efficacy.
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Replication-competent (attenuated) viral vectors. 
Vesicular stomatitis virus (VSV), a negative sense RNA 
virus of the Rhabdoviridae family, has become a 
prominent replication-competent vaccine vector platform 
[16]. VSV is non-pathogenic in humans and has an 
inherent ability to elicit strong cellular and humoral 
immune responses. One of the most useful aspects of this 
virus vector platform is its almost promiscuous ability to 
assemble recombinant VSV (rVSV), with many different 
types of heterologous viral glycoproteins. The platform is 
designed such that the VSV G protein is replaced with a 
heterologous envelope glycoprotein from, for example, an 
emerging virus; while this arrangement renders the rVSV 
replication competent, the recombinant viruses are 
generally highly attenuated [17].
In 1937, the attenuation of a yellow fever (YF) virus 
via successive rounds of serial passage led to the develop-
ment of the YF vaccine termed 17D. The impact of this 
successful vaccine was recognized by the award of a Nobel 
Prize in 1956 [18] and it has been widely adopted for 
human immunization for more than 70 years [19]. Based 
on the utility of the vaccine, an infectious cDNA clone 
of the YF17D virus [20] has enabled the development of 
a 17D platform that can be used to drive antigen delivery 
of pathogens of interest [21]. The technology (licenced 
as ChimeriVax™) is well suited to similarly related flavi-
viruses and successful recombinants have been constructed, 
involving a simple swap of the PrM/M-E genes of YF17D 
for the same membrane envelope antigens of other emerg-
ing flaviviruses, such as Japanese encephalitis, Dengue and 
West Nile. The resulting recombinant vaccines are effi-
ciently delivered in a live-attenuated virus context with 
the safety profile afforded by the 17D non-structural genes 
[22]. A licenced vaccine for Japanese encephalitis 
(ChimeriVax™-JE) using this technology has been devel-
oped by Sanofi Pasteur (Lyon, France).
Other replication-competent platforms. The ease of 
direct manipulation of viral genomes together with a 
growing understanding of their biology has led to the 
development of attenuated virus vaccines with increased 
safety and immunogenicity. For example, a new vaccine 
candidate for RVFV has been developed in which a viral 
virulence factor has been deleted, resulting in a highly 
attenuated but immunogenic replicating virus [23]. A 
similar recombinant approach has been used to attenuate 
the emerging and neglected pathogen Mayaro virus (MAYV) 
by swapping the subgenomic promoter of this alphavirus for 
an internal ribosome entry site [24,25], which reduces the 
expression of MAYV structural proteins. While this 
Fig. 1. Virus vector platform technologies. Replication competent but attenuated virus vectors (RHS) deliver heterologous antigen targets resulting in 
the induction of cellular and humoral responses. Their complement of genes enables a full round of replication and assembly of progeny virus which 
can amplify and spread the vaccine effect to susceptible cells. While these platforms are based on highly attenuated viral backgrounds, replication 
competence may lead to the development of mutations and reversion to virulence. Replication defective vectors (LHS) support effective cellular entry 
and a single round of expression of the target gene / antigen; they result in effective induction of cellular and humoral responses. They are unable to 
generate new infectious progeny and are considered safer than replication competent vectors.
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arrangement makes the virus unable to infect mosquito 
cells, replication in mammalian cells is still possible, 
resulting in a highly immunogenic profile. Similar studies 
on infectious clones of other viruses [26] have demonstrated 
that the genomewide de-optimization of codon usage 
dramatically reduces gene expression and can be used to 
attenuate otherwise pathogenic viruses. This strategy has 
been used for the prototype arenavirus lymphocytic 
choriomeningitis virus (LCMV) [27]; the study showed 
attenuation in an otherwise fatal mouse model of LCM 
disease and the ability to induce protective immunity. 
Together with a maintained and robust ability to multiply in 
cell culture, this live attenuated approach may be suitable 
for similar viruses. However, work to underpin confidence 
in the genetic stability of such attenuated viruses is critical 
before further consideration can be given to using this 
approach for clinical intervention, especially considering 
the inherent high error rates of the arenavirus 
polymerase.
Replication-defective approaches. For several years, 
recombinant adenoviruses have been adopted as promising 
tools for antigen delivery and vaccine efficacy [28]. Deleting 
the E1 gene from the adenoviral genome and supplying it in 
trans from a packaging cell line allows replication-deficient 
recombinant adenovirus to be produced, with the novel 
heterologous antigen gene of interest inserted at the E1 
locus. Early setbacks in this platform technology relating to 
pre-existing anti-adenovirus vector antibodies in humans 
[29] have been resolved by adopting simian adenoviruses as 
vaccine vectors. A number of different replication-deficient 
vaccine vectors [30] have recently been developed from 
simian adenoviruses and the platform has progressed work 
on emerging pathogens such as Ebola virus, RVFV MERS-
CoV and Zika virus.
Modified vaccinia virus Ankara (MVA) is licensed as 
a third-generation vaccinia type vaccine against smallpox 
and serves as a potent vector system for the development 
of new candidate vaccines against a range of infectious 
diseases, including those caused by emerging pathogens. 
Historically, MVA was developed by serial tissue culture 
passage in primary chicken cells of vaccinia virus strain 
Ankara, and clinically used to avoid the undesirable side 
effects of conventional vaccinia vaccines [31,32]. Adapted 
to growth in avian cells, MVA does not replicate in mam-
malian hosts and lacks many of the viral immune evasion 
genes [33]. The features of MVA, such as its capacity to 
accommodate large gene inserts [34], thermostability for 
application in remote regions without an established cold 
chain [35], ease of inexpensive manufacture to GMP 
standards and established regulatory package for develop-
ment as an Investigational New Drug, make the recom-
binant MVA platform [36] highly versatile as a heterologous 
viral vector. In the context of emerging infections, the 
recombinant MVA platform has shown encouraging pre-
clinical efficacy against Ebola, Zika, Chikungunya [37] 
and CCHF [38] viruses. Additionally, MVA elicits a strong 
immunological response against a range of other ortho-
poxviruses (OPXVs) (including Variola), and vaccines 
based on this platform can be considered as providing 
added value, as human immunity to OPXVs is low (after 
the cessation of the smallpox vaccination campaign) open-
ing a gap for OPXV emergence, as evidenced by the 
recent occurrence of monkeypox virus in West Africa 
and onward cross boarder transmissions [39,40].
RNA replicon systems are derived from either positive- or 
negative-strand RNA virus genomes and embody disabled 
virus vectors that are non-pathogenic and unable to revert 
to virulence. Driven by autonomous RNA replication, RNA 
replicons result in high-level, cytosolic expression of recom-
binant heterologous antigens stimulating both the humoral 
and cellular arms of the immune system. Replicon vaccine 
approaches have closely followed technical developments to 
genetically manipulate viral genomes. For RNA viruses, rep-
licons based on positive-stranded picornaviruses were some 
of the first [41], and these were followed by those based 
on alphaviruses [42] and negative-strand RNA viruses [43]. 
While a series of different vaccine replicon systems are avail-
able, new capabilities with negative-strand viruses have opened 
up opportunities against a wider range of emerging viruses. 
Recent developments [44] include the construction of LASV 
replicons packaged into LASV-like particles which allow a 
single round of replication and are able to confer protection 
against an otherwise lethal challenge of LASV in a guinea 
pig model of disease [44]. While recombinant replicons are 
devoid of the viral glycoprotein gene, its incorporation into 
VLPs is achieved by the use of a cell line that expresses 
the glycoprotein separately (in trans). This enables the scal-
able propagation of replicon particles in a way that aims 
to combine the safety of replicon-delivered LASV antigens 
with the convenience of simply and rapidly producing an 
attenuated virus. Similar replicon approaches have been used 
to develop promising replicon-based vaccine candidates for 
Ebola virus [45] and RVFV [46].
Replicon approaches have the potency of live attenuated 
vaccines but are inherently safer, as their design ensures 
a single cycle of replication in contrast to a fully replicat-
ing, live attenuated vaccine virus. For live attenuated RNA 
virus vaccines which incorporate error-prone polymerases, 
reversion to virulence is a distinct possibility after multiple 
rounds of replication.
Virus-like particles
Interest in the use of virus-like particles (VLPs) as vac-
cines candidates stems from their ability to present 
ordered and highly antigenic structures to the immune 
system. At the same time, they lack a viral genome, 
potentially yielding safer vaccines, as there is no viral 
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sequence that can revert to virulence. They induce strong 
B cell responses in the absence of adjuvants by efficiently 
cross-linking specific receptors on B cells [47], and they 
can also trigger T cell-mediated responses [48]. The 
basis of ordered viral self-assembly from protein subunits 
that is noted in many different virus families provides 
the foundation for work with VLPs, with more than 
30 different viruses that infect humans or other animals 
being identified as able to produce VLPs. They are 
structurally diverse, having single or multiple capsid 
proteins, or a lipid envelope, although not all viruses 
are suitable VLP candidates. Those which are can elicit 
a protective response without requiring multiple booster 
shoots, thus significantly reducing the vaccine costs. To 
date, VLP-based vaccines for human papilloma virus 
(HPV), hepatitis B virus (HBV) and hepatitis E virus 
(HEV) have been licensed and are commercially avail-
able worldwide [49]. Several VLP-based vaccine candi-
dates for human diseases are under clinical development, 
including those directed against Norwalk virus, Ebola 
and Marburg viruses and hepatitis C virus. VLP vac-
cines combine many of the immunogenic advantages 
of whole-virus vaccines with the safety advantages of 
recombinant subunit vaccines.
Nucleic acid vaccines
DNA vaccines have emerged as a safer alternative to 
standard live and inactivated vaccines for treating human 
and animal infections [50]. They exhibit several advantages 
over traditional strategies in terms of safety, stability, ease 
of manufacturing and immunogenicity [51]. They offer 
potential advantages for vaccination against emerging 
viruses, in that plasmids expressing a viral antigen can 
be produced rapidly. Furthermore, antigen is expressed 
in vivo and induces both humoral and cell-mediated 
immune responses. Additionally, large quantities of DNA 
can be produced in a short time at reduced cost, and 
DNA preparations are more stable than other types of 
vaccines, which are desirable properties for a vaccine that 
may be used in remote areas. Furthermore, DNA vaccines 
are considered safe. However, the main limitation in the 
development of DNA vaccines is their intrinsic low immu-
nogenicity. Work to improve this has focused on opti-
mizing delivery approaches with the use of gene guns, 
or electroporation; targeting immune effector cells; and 
the use of potent adjuvants. DNA vaccines are also fre-
quently used in combination with other vaccine platforms 
in heterologous prime-boost strategies.
A DNA vaccine is currently licensed to immunize horses 
against West Nile virus [52] and has undergone Phase I 
clinical trials in humans [53]. DNA vaccines have also 
been evaluated as candidates against many emerging 
viruses, including EBOV [54], RVFV [55], Dengue virus 
[56] and CHIKV [57].
Synthetic peptides
Synthetic peptide-based epitope-vaccines (EVs) make use 
of short antigen-derived peptide fragments that can be 
presented either to T cells or B cells [58]. EVs offer 
several advantages over other forms of vaccines, particu-
larly with regard to safety, ease of production, storage 
and distribution, without cold chain issues. They also offer 
the opportunity to vaccinate against several pathogens or 
multiple epitopes from the same pathogen. However, 
drawbacks include poor immunogenicity and the restric-
tion of the approach to patients of a given tissue type 
[human leucocyte antigen (HLA) haplotype] [59] and, as 
such, they need to be tailored to accommodate the natural 
variation in HLA genes. Although initially this was thought 
to be a major impediment, new technologies have made 
this personalized-medicine approach feasible [60,61]. 
Recently, bioinformatics tools have been developed to 
identify putative CD4+ T cell epitopes, mapped to the 
surface glycoproteins of the emerging viruses LASV, NipV 
and Hendra [62]. While these vaccine candidates still need 
to be experimentally tested, the approach represents an 
interesting and novel strategy that shows promise for 
vaccination and which could also address immunity in 
particular target populations.
Inactivated viruses
The induction of immune responses by the delivery of 
inactivated pathogens has been a standard and successful 
vaccination approach for many years, and licenced, inac-
tivated vaccines for diseases such as poliomyelitis [63] and 
rabies [64] are commercially available. The long history 
of this approach is underpinned by a well-defined regula-
tory framework that can be readily applied to new disease 
targets [65]. The major challenge for the inactivated virus 
approach is that infection is not established, and therefore 
a full adaptive immune response is generally not achieved. 
However, because of the absence of living pathogens, these 
types of vaccines are safe and a basic capability to prepare 
such vaccines, especially for emergency use, might be 
worthwhile as a stop-gap while alternative longer-term 
approaches are developed. In this regard, studies of virus 
inactivation with X-ray radiation (as a simple and cheap 
alternative to gamma irradiation by the use of radioactive 
isotopes), which maintain the tertiary antigenic structures 
of virus particles while destroying infectivity, have shown 
useful promise for a range of applications including vac-
cination (B. Afrough, unpublished).
Future perspectives
Vaccines play a pivotal role in host protection against 
infectious diseases and have significantly reduced mortality 
worldwide. However, many vaccine candidates for 
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emerging diseases have failed to make it into clinical 
development. This is perhaps surprising, given the breadth 
of vaccine technology available and the nature of many 
of the diseases in question. A case in point is Lassa fever, 
a viral haemorrhagic illness endemic to many parts of 
West Africa responsible for more than 300  000 cases of 
serious disease and approximately 3000 deaths each year 
since its discovery more than 50 years ago. It is often 
in the headlines, being the most commonly exported VHF 
to other territories, including the United Kingdom, which 
has received a disproportionate share of traveller-related 
cases (each incident placing substantial burden on public 
health resources). During 2018, LASV caused an unusually 
large increase in cases in Nigeria, which led the WHO 
to classify it as a grade 2 public health emergency. However, 
despite the high burden of Lassa fever and public atten-
tion, no vaccines have so far been approved. Multiple 
approaches to develop a range of effective preclinical 
candidates have been made during the last three decades, 
including attenuated vaccines [66], replication competent 
vaccines, [67–69], non-replicating LASV vaccines [47], a 
rationally designed live attenuated vaccine [70] and DNA 
vaccines [71]. Additionally, many of these platforms have 
shown efficacy in animal models including NHPs 
[67,72,73].
These preclinical data illustrate that multiple vaccine 
technologies have the potential to yield protective Lassa 
fever vaccines. Therefore, the lack of a clinical vaccine 
after 50 years since the disease was first described must 
be due to other factors, such as economic considerations 
or safety issues, perhaps connected with the growing bur-
den of regulatory thresholds for human medical interven-
tions. Thus, bringing a LASV vaccine and, by analogy, 
other potential vaccines for emerging diseases to the clinic, 
may be very difficult – for non-technical reasons. Although 
there is renewed interest from multiple international agen-
cies to develop human vaccines for certain emerging 
pathogens [74,75], it is prudent to consider other 
approaches to the control of emerging disease, including 
the feasibility of controlling infections at source.
The pattern of disease emergence from viral pathogens 
into humans from wildlife reservoirs is a clear and present 
threat [1–5] which will continue. This makes the task of 
identifying, controlling and preventing zoonoses a difficult 
and daunting goal, particularly when a new emerging 
pathogen may be completely unknown. While surveillance 
is an essential component of a successful control pro-
gramme, effective containment of an emerging pathogen, 
before epizootics have the opportunity to spill over into 
human populations, has been achieved most effectively 
by large-scale culling or mass vaccination [76,77] of ani-
mals. Nevertheless, the ability to contain even known 
emerging viruses such as Ebola virus in wildlife is cur-
rently not possible. Furthermore, the management of 
diseases that involve livestock, such as RVF and CCHF, 
pose problems [78,79] in that conventional vaccines are 
not suited for use in these environments. A major limita-
tion of conventional vaccination is the requirement for 
individual inoculation of each animal  –  a costly and 
impractical strategy for the target/reservoir species of those 
animals frequently involved in the emergence of high-risk 
pathogens [1].
Surveillance work focusing on epizootics that are, or 
may become, human pathogens is a useful goal. Currently 
however, predicting which animal pathogens will become 
established as globally significant emerging human diseases 
is guesswork. Nevertheless, in the early stages of a new 
zoonosis, pathogenic viruses are often poorly adapted to 
their new human host in terms of sustained human-to-
human transmission [80]. This lag-phase in early zoonosis 
may, therefore, provide a window of opportunity to control 
the unrelenting zoonotic pressure of an emerging pathogen 
before it adapts further to humans. Vaccine targeting of 
the pathogen within the animal transmission species could 
therefore bring useful advantages.
Self-disseminating wild-life reservoir vaccines
Self-disseminating vaccines, which aim to immunologi-
cally contain emerging viruses within their non-human 
reservoir hosts, offer an alternative to the conventional 
vaccine approach. They are designed to exploit the ability 
of replicating virus-based vectors to spread through ani-
mal host populations, so avoiding the need for direct 
inoculation of every animal. In this way, vaccination of 
a limited number of initiator animals is used for the 
introduction of the vaccine into a target population. The 
vaccine is engineered to express target antigens from 
the emerging pathogen of interest, so its transmission 
from vaccinated to non-vaccinated animals will result 
in the co-ordinated spread of specific immunity for the 
emerging pathogen throughout the targeted animal 
population.
Following early work to underpin a proof of principle 
for a disseminating vaccine against an animal pathogen 
[81,82], a study targeting the human pathogen Sin Nombre 
orthohantavirus (SNV) in its rodent reservoir  –  the deer 
mouse (Peromyscus maniculatus)  –  proved effective. This 
approach used an engineered cytomegalovirus (CMV) 
vector (which causes a benign but transmissible infection 
in the host), expressing the SNV envelope glycoprotein 
G1 [83]. A similar approach is also being developed to 
interrupt zoonotic transmission of Ebola virus [84], in 
this case disseminating CMV vaccines specific to great 
apes and expressing EBOV antigens are being studied in 
African ape populations in the wild [85]. Interestingly, 
one of the goals of this work is to protect the great apes 
themselves from Ebola virus disease, a major threat to 
the survival of these animals in the wild. Also, as 
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approximately 30% of human Ebola virus outbreaks are 
known to have resulted from the direct handling of infected 
ape carcasses, the disseminating CMV-based strategy may 
be significant in protecting humans [86]. Clearly, further 
work needs to be conducted to assess the risks of live 
transmissible vaccines evolving into a pathogen with 
increased virulence. Engineering such wild-life reservoir 
vaccines to be weakly transmitting, such that their repro-
duction number is below 1 (R0  <  1), making their trans-
mission chains short so that they cannot be maintained, 
might be a way to address the justifiable safety risks. 
Indeed, a mathematical model has recently demonstrated 
the value of such an approach [87].
Conclusions
Emerging pathogens represent one of the greatest risks 
to global health. There is already good evidence [1,5] that 
zoonotic pathogens will most probably be transmitted 
from a few key animal species in resource-poor areas of 
the world. Based on recent history, it is probable that 
such pathogens have never been seen before. The global 
impact of the West African outbreak of Ebola virus in 
2014 underlines how stark differences in health-care infra-
structure can impact upon human-to-human transmission 
of emerging pathogens. Until basic health-care infrastruc-
ture in all countries can be raised to a level that enables 
early identification and control of high-risk pathogens at 
source, we will continue to respond to outbreaks of emerg-
ing disease long after epizootics have spilled over into 
human populations. Innovative strategies are therefore 
urgently required to control such pathogens, vaccination 
is a proven approach.
Many novel vaccination strategies that have been 
developed during recent years have the potential to 
specifically address the growing threat of new and emerg-
ing disease. The use of well-defined vaccine vector plat-
forms, with an extensive record of safety and efficacy 
against similar pathogens, can expedite the process of 
development, validation and production (Table 1). 
Accordingly, the design and licensure for particular 
platform vaccine technologies will help to accelerate the 
development of new vaccines, as only the simple sub-
stitution of a new antigen gene into the vector platform 
is required. This allows manufacturers to move to a 
new target disease with minimal changes in chemistry, 
manufacturing and controls. Thus, new vaccine develop-
ment can focus on the safety and efficacy of the inserted 
gene. In addition, the ability of platforms to target 
multiple pathogens helps to justify the investment 
required to build and maintain manufacturing infra-
structure that specializes in one platform, because a 
single manufacturing facility can be ready to produce 
multiple vaccines at any time.
In addition, further research into, and the development 
of, self-disseminating vaccines to control potential patho-
gens in their wild-life reservoirs should be encouraged. 
However, the progress of new vaccines through the neces-
sary regulatory pathways to bring them to the clinic 
requires long-term investment by governments and inter-
national organizations.
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